Trial · NCT02425449
Fade Upon TOF Stimulation Induced by Succinylcholine
NCT02425449, Phase 4, Completed, University of Toledo Health Science Campus; results first posted 2018-01-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Fade Upon TOF Stimulation Induced by Succinylcholine. Trials, record NCT02425449. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02425449
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Fade Upon TOF Stimulation Induced by Succinylcholine
- NCT number
- NCT02425449
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 19 participants, actual
- Lead sponsor
- University of Toledo Health Science Campus
- Conditions
- Muscle Relaxants
- Interventions
- Succinylcholine
- First posted
- 2015-04-24
- Last updated
- 2018-01-02
- Results first posted
- 2018-01-02
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Fade on Train of Four Stimulation | for the duration of the effect of succinylcholine generally expected to be 6-10 minutes | We stimulated the ulnar nerve at the wrist four times (over 1.5 seconds) every 20 seconds. We measured the ratio of the fourth contraction to the first contraction before and after the administration of succinylcholine. Before administering succinylcholine the ratio is normally one. After the administration of succinylcholine the first contraction diminishes, but the fourth contraction diminishes even more. This results in a ratio of T4 to T1 being less than one. The lowest ratio recorded after the administration after the administration of succinylcholine is reported as our outcome measure. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Fade on Train of Four Stimulation | for the duration of the effect of succinylcholine generally expected to be 6-10 minutes | Ratio | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Fade on Train of Four Stimulation | Arm 2 | 0.85 | Standard Deviation 0.02 | Ratio | |
| Fade on Train of Four Stimulation | Arm 3 | 0.64 | Standard Deviation 0.04 | Ratio | |
| Fade on Train of Four Stimulation | Arm 4 | 0.66 | Standard Deviation 0.09 | Ratio | |
| Fade on Train of Four Stimulation | Arm 5 | 0.68 | Standard Deviation 0.04 | Ratio |
Source ClinicalTrials.gov
Participant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm 1 | 0 | |
| Overall Study | STARTED | Arm 2 | 4 | |
| Overall Study | STARTED | Arm 3 | 5 | |
| Overall Study | STARTED | Arm 4 | 5 | |
| Overall Study | STARTED | Arm 5 | 5 | |
| Overall Study | COMPLETED | Arm 1 | 0 | |
| Overall Study | COMPLETED | Arm 2 | 4 | |
| Overall Study | COMPLETED | Arm 3 | 5 | |
| Overall Study | COMPLETED | Arm 4 | 5 | |
| Overall Study | COMPLETED | Arm 5 | 5 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals15
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm 1 | 0 | 0 |
| Total, all-cause mortality | Arm 2 | 0 | 4 |
| Total, all-cause mortality | Arm 3 | 0 | 5 |
| Total, all-cause mortality | Arm 4 | 0 | 5 |
| Total, all-cause mortality | Arm 5 | 0 | 5 |
| Total, other adverse events | Arm 1 | 0 | 0 |
| Total, other adverse events | Arm 2 | 0 | 4 |
| Total, other adverse events | Arm 3 | 0 | 5 |
| Total, other adverse events | Arm 4 | 0 | 5 |
| Total, other adverse events | Arm 5 | 0 | 5 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02425449
GET https://conductscience.org/api/trials/v1/NCT02425449/registered